ABL Bio (298380.KQ) Stock Price

ABL Bio Price

KRX·CLOSED
81,600.00KRW+1,200.00 (+1.48 %)
Market closed

Over the last 8 years ABL Bio grew revenue by 140.3% annually, reaching 79.35 B KRW. For ABL Bio, the net margin of -47.6% is up versus -816.9% a few years ago. The consensus 12-month price target for ABL Bio is 214,200.00 KRW, about 162.5% above where the stock trades today. Of 10 analysts, 9 rate the stock a buy — an overall Buy consensus. The stock trades about 33% above its 52-week low.

ABL Bio stock price

Volume
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of ABL Bio over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how ABL Bio stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing ABL Bio's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

ABL Bio Stock Price History
DateABL Bio Price
8/5/202681,600.00 KRW
8/4/202680,400.00 KRW
8/3/202672,600.00 KRW
7/31/202666,800.00 KRW
7/30/202661,500.00 KRW
7/29/202663,300.00 KRW
7/28/202668,800.00 KRW
7/27/202673,300.00 KRW
7/24/202672,400.00 KRW
7/23/202674,300.00 KRW
7/22/202669,400.00 KRW
7/21/202669,300.00 KRW
7/20/202671,200.00 KRW
7/16/202675,600.00 KRW
7/15/202679,400.00 KRW
7/14/202672,000.00 KRW
7/13/202679,900.00 KRW
7/10/202683,200.00 KRW
7/9/202680,600.00 KRW
7/8/202681,800.00 KRW
7/7/202693,900.00 KRW
7/6/202690,200.00 KRW
7/3/202694,300.00 KRW
7/2/202697,200.00 KRW
7/1/2026102,600.00 KRW
6/30/2026100,700.00 KRW
6/29/2026107,600.00 KRW
6/26/202688,700.00 KRW
6/25/202698,000.00 KRW
6/24/202696,700.00 KRW
6/23/202692,100.00 KRW
6/22/202697,700.00 KRW
6/19/202698,900.00 KRW
6/18/2026101,400.00 KRW
6/17/2026112,700.00 KRW
6/16/202698,100.00 KRW
6/15/202693,500.00 KRW
6/12/202693,500.00 KRW
6/11/202690,300.00 KRW
6/10/202690,200.00 KRW
6/9/202692,400.00 KRW
6/8/202688,600.00 KRW
6/5/202699,800.00 KRW
6/4/2026106,000.00 KRW
6/2/2026107,100.00 KRW
6/1/2026111,900.00 KRW
5/29/2026111,900.00 KRW
5/28/2026114,500.00 KRW
5/27/2026118,500.00 KRW
5/26/2026117,500.00 KRW
5/22/2026120,200.00 KRW
5/21/2026109,900.00 KRW
5/20/2026106,300.00 KRW
5/19/2026112,000.00 KRW
5/18/2026112,200.00 KRW
5/15/2026119,300.00 KRW
5/14/2026125,600.00 KRW
5/13/2026123,900.00 KRW
5/12/2026130,000.00 KRW
5/11/2026127,700.00 KRW
5/8/2026130,100.00 KRW
5/7/2026126,400.00 KRW
5/6/2026127,600.00 KRW
5/4/2026132,500.00 KRW
4/30/2026134,800.00 KRW
4/29/2026142,000.00 KRW
4/28/2026139,400.00 KRW
4/27/2026172,700.00 KRW
4/24/2026157,200.00 KRW
4/23/2026153,500.00 KRW
4/22/2026150,400.00 KRW
4/21/2026155,900.00 KRW
4/20/2026160,200.00 KRW
4/17/2026161,500.00 KRW
4/16/2026163,900.00 KRW
4/15/2026163,800.00 KRW
4/14/2026155,900.00 KRW
4/13/2026155,000.00 KRW
4/10/2026157,700.00 KRW
4/9/2026155,600.00 KRW
4/8/2026158,400.00 KRW
4/7/2026153,800.00 KRW
4/6/2026154,400.00 KRW
4/3/2026156,800.00 KRW
4/2/2026159,800.00 KRW
4/1/2026180,100.00 KRW
3/31/2026165,900.00 KRW
3/30/2026171,600.00 KRW
3/27/2026179,900.00 KRW
3/26/2026179,900.00 KRW
3/25/2026172,300.00 KRW
3/24/2026172,900.00 KRW
3/23/2026168,800.00 KRW
3/20/2026190,500.00 KRW
3/19/2026190,000.00 KRW
3/18/2026195,500.00 KRW
3/17/2026191,000.00 KRW
3/16/2026187,000.00 KRW
3/13/2026188,000.00 KRW
3/12/2026181,200.00 KRW
3/11/2026182,400.00 KRW
3/10/2026185,200.00 KRW
3/9/2026189,700.00 KRW
3/6/2026190,300.00 KRW
3/5/2026177,100.00 KRW
3/4/2026152,900.00 KRW
3/3/2026184,600.00 KRW
2/27/2026194,000.00 KRW
2/26/2026191,100.00 KRW
2/25/2026187,400.00 KRW
2/24/2026190,000.00 KRW
2/23/2026189,500.00 KRW
2/20/2026188,000.00 KRW
2/19/2026194,600.00 KRW
2/13/2026184,400.00 KRW
2/12/2026189,200.00 KRW
2/11/2026187,000.00 KRW
2/10/2026185,800.00 KRW
2/9/2026189,200.00 KRW
2/6/2026177,600.00 KRW
2/5/2026186,100.00 KRW
2/4/2026192,600.00 KRW
2/3/2026201,500.00 KRW
2/2/2026198,300.00 KRW
1/30/2026197,700.00 KRW
1/29/2026245,500.00 KRW
1/28/2026241,500.00 KRW
1/27/2026243,500.00 KRW
1/26/2026241,000.00 KRW
1/23/2026198,000.00 KRW
1/22/2026179,600.00 KRW
1/21/2026177,100.00 KRW
1/20/2026201,000.00 KRW
1/19/2026196,700.00 KRW
1/16/2026197,500.00 KRW
1/15/2026192,600.00 KRW
1/14/2026192,200.00 KRW
1/13/2026195,200.00 KRW
1/12/2026201,500.00 KRW
1/9/2026204,500.00 KRW
1/8/2026215,500.00 KRW
1/7/2026210,500.00 KRW
1/6/2026201,000.00 KRW
1/5/2026212,000.00 KRW
1/2/2026195,500.00 KRW
12/30/2025200,000.00 KRW
12/29/2025199,400.00 KRW
12/26/2025199,000.00 KRW
12/24/2025187,500.00 KRW
12/23/2025187,000.00 KRW
12/22/2025185,400.00 KRW
12/19/2025190,400.00 KRW
12/18/2025186,600.00 KRW
12/17/2025182,100.00 KRW
12/16/2025190,400.00 KRW
12/15/2025195,800.00 KRW
12/12/2025190,000.00 KRW
12/11/2025196,300.00 KRW
12/10/2025203,000.00 KRW
12/9/2025186,200.00 KRW
12/8/2025186,800.00 KRW
12/5/2025190,600.00 KRW
12/4/2025201,000.00 KRW
12/3/2025201,000.00 KRW
12/2/2025199,900.00 KRW
12/1/2025196,800.00 KRW
11/28/2025188,000.00 KRW
11/27/2025174,800.00 KRW
11/26/2025173,400.00 KRW
11/25/2025166,000.00 KRW
11/24/2025173,100.00 KRW
11/21/2025178,800.00 KRW
11/20/2025177,300.00 KRW
11/19/2025169,900.00 KRW
11/18/2025166,600.00 KRW
11/17/2025176,000.00 KRW
11/14/2025174,200.00 KRW
11/13/2025163,500.00 KRW
11/12/2025126,700.00 KRW
11/11/202597,500.00 KRW
11/10/2025100,500.00 KRW
11/7/2025101,300.00 KRW
11/6/2025104,400.00 KRW
11/5/2025103,800.00 KRW
11/4/2025111,200.00 KRW
11/3/2025103,300.00 KRW
10/31/202599,700.00 KRW
10/30/202593,000.00 KRW
10/29/202593,000.00 KRW
10/28/202595,500.00 KRW
10/27/202594,400.00 KRW
10/24/202584,800.00 KRW
10/23/202585,000.00 KRW
10/22/202586,300.00 KRW
10/21/202587,500.00 KRW
10/20/202587,500.00 KRW
10/17/202585,800.00 KRW
10/16/202586,300.00 KRW
10/15/202590,100.00 KRW
10/14/202590,000.00 KRW
10/13/202591,500.00 KRW
10/10/202593,900.00 KRW
10/2/202595,900.00 KRW
10/1/202595,000.00 KRW
9/30/202592,400.00 KRW
9/29/202593,300.00 KRW
9/26/202592,200.00 KRW
9/25/202593,300.00 KRW
9/24/202598,800.00 KRW
9/23/2025107,900.00 KRW
9/22/2025108,300.00 KRW
9/18/202598,600.00 KRW
9/17/202599,900.00 KRW
9/16/2025101,300.00 KRW
9/15/2025104,200.00 KRW
9/12/2025105,300.00 KRW
9/11/2025105,400.00 KRW
9/10/2025102,900.00 KRW
9/9/2025103,000.00 KRW
9/8/2025100,300.00 KRW
9/5/2025103,000.00 KRW
9/4/202595,500.00 KRW
9/3/202596,900.00 KRW
9/2/202593,000.00 KRW
9/1/202590,500.00 KRW
8/29/202591,600.00 KRW
8/28/202594,700.00 KRW
8/27/202594,800.00 KRW
8/26/202594,400.00 KRW
8/25/202588,800.00 KRW
8/22/202581,800.00 KRW
8/21/202581,100.00 KRW
8/20/202580,900.00 KRW
8/19/202583,100.00 KRW
8/18/202589,700.00 KRW
8/14/202587,400.00 KRW
8/13/202581,600.00 KRW
8/12/202577,200.00 KRW
8/11/202577,500.00 KRW
8/8/202574,500.00 KRW
8/7/202574,100.00 KRW
Access this data via the Eulerpool API
Get Free API Key

ABL Bio Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2019
3.99 B KRW
-40.43 B KRW
-37.00 B KRW
Jan 1, 2020
8.10 B KRW
-59.65 B KRW
-55.61 B KRW
Jan 1, 2021
5.33 B KRW
-52.31 B KRW
-43.56 B KRW
Jan 1, 2022
67.30 B KRW
906.48 M KRW
3.21 B KRW
Jan 1, 2023
65.55 B KRW
-2.62 B KRW
-2.65 B KRW
Jan 1, 2024
33.40 B KRW
-59.38 B KRW
-55.53 B KRW
Jan 1, 2025
79.35 B KRW
-40.28 B KRW
-37.81 B KRW
Jan 1, 2026 (e)
89.00 B KRW
-43.57 B KRW
252.11 M KRW

ABL Bio Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 6, 2026, 3:44 AM
 
REVENUEB KRW
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEB KRW
EBITB KRW
EBIT MARGIN%
NET INCOMEB KRW
NET INCOME GROWTH%
SHARESM
20162017201820192020202120222023202420252026e
–0.071.263.998.105.3367.3065.5533.4079.3589.00
––1,670.42217.26103.21-34.211,162.19-2.60-49.04137.5512.16
–5.6391.6599.20100.00100.00100.00100.00100.00100.00100.00
79.35–1.153.968.105.3367.3065.5533.4079.3589.00
-3.52-9.65-24.03-40.43-59.65-52.310.91-2.62-59.38-40.28-43.57
–-13,590.14-1,911.46-1,013.74-736.02-980.961.35-3.99-177.76-50.76-48.96
-13.68-74.73-117.23-37.00-55.61-43.563.21-2.65-55.53-37.810.25
–446.1456.87-68.4450.27-21.67-107.37-182.481,998.60-31.92-100.67
44.5944.5944.5944.5944.5944.5944.5944.5944.5944.5944.59
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales ABL Bio generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue ABL Bio retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare ABL Bio's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares ABL Bio has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against ABL Bio's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

ABL Bio stock margins

The ABL Bio margin analysis displays the gross margin, EBIT margin, as well as the profit margin of ABL Bio. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for ABL Bio.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2019
99.18 %
-1,013.52 %
-927.68 %
Jan 1, 2020
100.00 %
-736.00 %
-686.14 %
Jan 1, 2021
100.00 %
-980.96 %
-816.91 %
Jan 1, 2022
100.00 %
1.35 %
4.77 %
Jan 1, 2023
100.00 %
-3.99 %
-4.04 %
Jan 1, 2024
100.00 %
-177.76 %
-166.24 %
Jan 1, 2025
100.00 %
-50.76 %
-47.65 %
Jan 1, 2026 (e)
100.00 %
-48.96 %
0.28 %

ABL Bio Stock Revenue, EBIT, Earnings per Share

The ABL Bio earnings per share therefore indicates how much revenue ABL Bio has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2019
0.00 KRW
0.00 KRW
0.00 KRW
Jan 1, 2020
0.00 KRW
0.00 KRW
0.00 KRW
Jan 1, 2021
0.00 KRW
0.00 KRW
0.00 KRW
Jan 1, 2022
0.00 KRW
0.00 KRW
0.00 KRW
Jan 1, 2023
0.00 KRW
0.00 KRW
0.00 KRW
Jan 1, 2024
0.00 KRW
0.00 KRW
0.00 KRW
Jan 1, 2025
0.00 KRW
0.00 KRW
0.00 KRW
Jan 1, 2026 (e)
1,853.34 KRW
-977.20 KRW
5.25 KRW

ABL Bio business model & stock analysis

ABL Bio Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

ABL Bio historical P/E ratio, EBIT multiple, and P/S ratio

ABL Bio annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

ABL Bio shares outstanding

The number of shares of ABL Bio was 44.59 M in 2025. This indicates how many shares ABL Bio is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2019
44.59 M Stocks
Jan 1, 2020
44.59 M Stocks
Jan 1, 2021
44.59 M Stocks
Jan 1, 2022
44.59 M Stocks
Jan 1, 2023
44.59 M Stocks
Jan 1, 2024
44.59 M Stocks
Jan 1, 2025
44.59 M Stocks
Jan 1, 2026 (e)
44.59 M Stocks

Current ABL Bio forecasts and price targets in August 2026

Analyst Price Targets 2026
Δ MOM Price Target
31.25 %
Buy
90.00 % (9)
Hold
10.00 % (1)
Sell
0.00 % (0)
12M Price Target
214,200.00
Last Price
81,600.00
Currency
KRW
12M Return Potential
162.50 %
LTM Return
0 %

ABL Bio shareholder structure

% Name
2.05598%
The Vanguard Group, Inc.
The Vanguard Group, Inc.
1.69175%
Samsung Asset Management Co., Ltd.
Samsung Asset Management Co., Ltd.
0.89992%
BlackRock Institutional Trust Company, N.A.
BlackRock Institutional Trust Company, N.A.
0.51683%
Mirae Asset Global Investments Co., Ltd.
Mirae Asset Global Investments Co., Ltd.
0.37787%
BlackRock Advisors (UK) Limited
BlackRock Advisors (UK) Limited
0.28930%
KB Asset Management Co., Ltd.
KB Asset Management Co., Ltd.

ABL Bio Beneficial Ownership Filings (SEC 13D/G)

Free Float
74.3%
Float Shares
-
Shares Outstanding
-

ABL Bio Executives and Management Board

8 members · avg. age 54 · 13 % women

JL

Mr. Jae Cheon Lee (51)

Chief Financial Officer, Managing Director

768.00 M KRW

Management

SL

Mr. Sang Hun Lee (59)

Chief Executive Officer, Director

–
JJ

Mr. Jae Ho Jung (59)

Managing Director

–
JK

Mr. Jeong Dae Kim (58)

Managing Director

–
JW

Mr. Jong Hwa Won (58)

Managing Director

–
WY

Mr. Won Gyu Yoo (53)

Managing Director

–

Board of Directors

JC

Ms. Jeong Hye Choi (43)

Non-Executive Independent Director

–
DK

Mr. Dong Yun Kim (52)

Non-Executive Independent Director

–

Frequently asked questions about ABL Bio

Analysts currently set an average price target of 185,980.00 KRW for the ABL Bio stock (median: 214,200.00 KRW), implying +127.9 % versus the latest price. The consensus is based on 10 analyst ratings.

ABL Bio Analyst Price Targets 2026

10 analysts currently rate the ABL Bio stock: 9 recommend buying, 1 holding and 0 selling. For 2026, analysts expect ABL Bio to generate revenue of 89.00 B KRW and earnings per share of 5.65 KRW.

ABL Bio Analyst Price Targets 2026

Converted at the current exchange rate, the ABL Bio share trades at 49.65 EUR (81,600.00 KRW).

No history available for ABL Bio.

The expected revenue of ABL Bio is 89.00 B KRW. This figure is based on current financial data and reflects the company's business performance.

The expected profit of ABL Bio is 252.11 M KRW. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of ABL Bio is currently 14,431.23. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the ABL Bio stock.

The price-to-sales ratio (P/S) of ABL Bio is currently 40.88. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the ABL Bio stock.

The Eulerpool Quality Score for ABL Bio is 2/10.

The ISIN of ABL Bio is KR7298380007. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of ABL Bio is 298380.KQ. The ticker symbol is used to trade ABL Bio shares on the stock exchange.

ABL Bio paid dividends every year for the past 0 years.

ABL Bio is assigned to the 'Health' sector.

The dividends of ABL Bio are distributed in KRW.

All fundamentals and in-depth analysis of ABL Bio

Our stock analysis for ABL Bio stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of ABL Bio. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

ABL Bio Stock
ABL Bio Revenue→
ABL Bio Stock
ABL Bio Net Income→
ABL Bio Stock
ABL Bio P/E→
ABL Bio Stock
ABL Bio P/S→
ABL Bio Stock
ABL Bio EBIT→
ABL Bio Stock
ABL Bio Dividend→
ABL Bio Stock
ABL Bio Directors Dealings→
ABL Bio Stock
ABL Bio Stocks→
ABL Bio Stock
ABL Bio Market capitalization→
ABL Bio Stock
ABL Bio Debt→
ABL Bio Stock
ABL Bio Liabilities→
ABL Bio Stock
ABL Bio Equity→
ABL Bio Stock
ABL Bio AAQS→
ABL Bio Stock
ABL Bio Employees→
ABL Bio Stock
ABL Bio ROE→
ABL Bio Stock
ABL Bio ROA→
ABL Bio Stock
ABL Bio ROCE→
ABL Bio Stock
ABL Bio News→
ABL Bio Stock
ABL Bio Analyst Price Targets→

Health Stocks

Abnova TaiwanAbivax SA American Depositary SharesAbsciAbivaxAC ImmuneAbionyx PharmaAcadia Healthcare CompanyAbionACADIA PharmaceuticalsAbingdon HealthAcarixAbera BioscienceAll Stocks A–Z →